S(MeO)TLC overcomes Gemcitabine resistance.

<p>A: The IC50s of Gemcitabine in KU7、KU7-Gr、RT112 and RT112-Gr in 72 hours. B: The IC50s of S(MeO)TLC of KU7、KU7-Gr、RT112 and RT112-Gr in 72 hours. C: KU7-Gr and RT112-Gr cells were left untreated or were treated with 45nM Gemcitabine (GEM), 0.5μM S(MeO)TLC or both together (GEM+ S(MeO)TLC). Seventy-two hours later viability was analyzed by Trypan blue staining. S(MeO)TLC and GEM+ S(MeO)TLC, inhibiting tumor effect is the best among the four group. Quantification of each value is from triplicate independent experiments. (<i>p</i> < 0.01).